| Aug 12 |
Chemomab Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update
|
| Jul 30 |
Chemomab Therapeutics Announces Closing of $10 Million Private Placement
|
| Jul 26 |
Chemomab Therapeutics regains compliance with Nasdaq
|
| Jul 26 |
Chemomab Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement
|
| Jul 25 |
Chemomab falls on private placement despite mid-stage win for lead asset
|
| Jul 25 |
Chemomab Therapeutics Announces $10 Million Private Placement
|
| Jul 25 |
Chemomab Therapeutics Announces Positive Phase 2 Trial Results: CM-101 Achieves Primary and Secondary Endpoints Demonstrating Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Effects in Patients with Primary Sclerosing Cholangitis
|
| Jun 18 |
Chemomab Therapeutics Announces New Publications Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis
|
| Jun 6 |
Chemomab Therapeutics Presents Data Supporting the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2024 and a Gordon Research Conference
|
